Researchers from Genequantum Healthcare (Suzhou) Co. Ltd. have presented the first preclinical data on GQ-1007, an antibody immune agonist conjugate (AIAC) targeting HER2, for the treatment of cancer. GQ-1007 is an anti-HER2 antibody conjugated via Genequantum’s highly stable linker and enzymatic conjugation technology to a Toll-like receptor 7/8 (TLR7/8) agonist.
Briacell Therapeutics Corp. has received IND clearance from the FDA to begin clinical studies with Bria-OTS, the first generation of the company’s personalized off-the-shelf cellular immunotherapy for breast cancer.
CSPC Pharmaceutical Group Ltd.’s SYS-6011 has been cleared by China’s National Medical Products Administration (NMPA) to enter clinical trials in China for solid tumors.
At the Society for Immunotherapy of Cancer’s annual meeting, researchers from Tallac Therapeutics Inc. reported the discovery of TAC-003, a novel Toll-like receptor 9 (TLR9) agonist and Nectin-4-specific antibody conjugate, being developed as cancer immunotherapy candidate.
Scientists at the University of California San Francisco (UCSF) have designed a group of synthetic molecules that could prevent the rejection of allogeneic cell transplants. Their strategy consisted of activating the immune checkpoints of different populations of immune cells from the cell surface, but avoiding the cytotoxicity of natural killer (NK) cells and macrophages that would destroy the transplanted cells.
Shares of Werewolf Therapeutics Inc. (NASDAQ:HOWL) reflected enthusiasm on Wall Street for the prospect, albeit early stage, of systemically delivering a masked native interleukin-2 (IL-2) cytokine to cancer patients.
Angiex Inc. has received FDA clearance of its IND application for AGX-101, a novel TM4SF1-directed antibody-drug conjugate (ADC) being developed for the treatment of solid cancers.
Researchers from Medigene AG recently presented the discovery and preclinical evaluation of first-in-class, third-generation T-cell receptor T-cell (TCR-T) therapies, MDG-1015 and MDG-2011.
RSS
